Astria Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Astria Therapeutics

07/05/2024 13:03

* Astria Therapeutics Inc  ATXS.OQ   ATXS.O  is expected
to show
no change in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Astria Therapeutics Inc
is for
a loss of 36 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Astria
Therapeutics Inc is $25.00​, above​ its last closing price
of $9.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.78       -0.78      -0.94     Missed  -20.5
 Sep. 30 2023  -0.46       -0.49      -0.63     Missed  -29.6
 Jun. 30 2023  -0.49       -0.49      -0.45     Beat    7.6​
 Mar. 31 2023  -0.57       -0.55      -0.40     Beat    27.5
 ​​Dec.        -0.57       -0.71      -0.72     Missed  -1.2
 31 2022                                                
 Sep. 30 2022  -0.91       -0.92      -0.87     Beat    5.2​
 Jun. 30 2022  -0.99       -1.01      -0.86     Beat    15.3
 Mar. 31 2022  -0.72       -0.73      -1.18     Missed  -62.1
 This summary was machine generated May 7 at 12:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)